Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 2,64 M
EBIT 2016 -58,2 M
Net income 2016 -58,4 M
Debt 2016 -
Yield 2016 -
Sales 2017 0,47 M
EBIT 2017 -63,9 M
Net income 2017 -63,3 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 47,1x
Capi. / Sales2017 262x
Capitalization 124 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on developing and commercializing products to treat treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic... 
More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating :
More Ratings
Latest news on ANTA PHAR
08/17 ANTHERA PHARMACEUTICALS : Announces Positive DSMB Review in Phase 3 SOLUTION Stu..
08/16 ANTHERA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financi..
08/16 Anthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as ..
08/16 Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION St..
08/09 ANTHERA PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fin..
08/09 ANTHERA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
08/09 ANTHERA PHARMACEUTICALS : reports 2Q loss
08/09 Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quar..
08/03 Anthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3..
08/02 ANTHERA PHARMACEUTICALS : Biotechnology Stocks on Investors' Radar -- Minerva Ne..
More news
Sector news : Bio Therapeutic Drugs
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/23DJPFIZER : to Acquire Key Drug -- WSJ
More sector news : Bio Therapeutic Drugs
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 10,6 $
Spread / Average Target 253%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Paul F. Truex Chief Executive Officer & Director
John Craig Thompson President & Chief Operating Officer
Christopher S. Henney Chairman
May Liu CAO, Senior VP-Finance & Administration
Chuck Olson Chief Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR124
AMGEN, INC.5.66%128 351
GILEAD SCIENCES, INC.-22.75%103 158
CELGENE CORPORATION-9.86%83 674
REGENERON PHARMACEUTIC..-26.43%42 053
VERTEX PHARMACEUTICALS..-22.96%24 020
More Results